Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$1.64 - $2.48 $725,209 - $1.1 Million
-442,201 Reduced 71.27%
178,258 $352,000
Q2 2022

Aug 15, 2022

BUY
$1.55 - $6.95 $961,711 - $4.31 Million
620,459 New
620,459 $973,000

Others Institutions Holding VAXX

About Vaxxinity, Inc.


  • Ticker VAXX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 112,150,000
  • Description
  • Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that...
More about VAXX
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.